HUTCHMED China Ltd (0013)

Hong Kong
Currency in HKD
20.90
-0.05(-0.24%)
Delayed Data
0013 Scorecard
Full Analysis
Management has been aggressively buying back shares
Fair Value
Day's Range
20.5521.20
52 wk Range
19.8035.90
Key Statistics
Edit
Bid/Ask
20.90 / 20.95
Prev. Close
20.95
Open
20.9
Day's Range
20.55-21.2
52 wk Range
19.8-35.9
Volume
5.85M
Average Volume (3m)
4.92M
1-Year Change
-4.56%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
0013 Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Holds more cash than debt on its balance sheet
Show more

HUTCHMED China Ltd Company Profile

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton’s tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.

Employees
1970
Market
Hong Kong

Compare 0013 to Peers and Sector

Metrics to compare
0013
Peers
Sector
Relationship
P/E Ratio
−53.3x−0.7x−0.6x
PEG Ratio
6.01−0.010.00
Price/Book
3.0x0.6x2.6x
Price / LTM Sales
3.7x2.2x3.1x
Upside (Analyst Target)
85.2%291.7%48.2%
Fair Value Upside
Unlock16.2%8.0%Unlock

Earnings

Latest Release
-
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

FAQ

What Is the Hutchison China (0013) Stock Price Today?

The Hutchison China stock price today is 20.90.

What Stock Exchange Does Hutchison China Trade On?

Hutchison China is listed and trades on the Hong Kong stock exchange.

What Is the Stock Symbol for Hutchison China?

The stock symbol for Hutchison China is "0013."

What Is the Hutchison China Market Cap?

As of today, Hutchison China market cap is 17.40B.

What is Hutchison China Earnings Per Share?

The Hutchison China EPS is -0.049.

From a Technical Analysis Perspective, Is 0013 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.